Eli Lilly (LLY) may have jumped 5.3% yesterday and added $3B to its market cap following news...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY) may have jumped 5.3% yesterday and added $3B to its market cap following news that its Solanezumab drug helped slow the progress of Alzheimer's Disease in Phase III trials, but SA author Brian Wilson points out that "the results were not statistically significant." This means that the study can't be used for an NDA submission of solanezumab, which is therefore "not going to make it to...market."